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j Abstract Following an arterial occlusion outward remodeling of
pre-existent inter-connecting arterioles occurs by proliferation of
vascular smooth muscle and endothelial cells. This is initiated by
deformation of the endothelial cells through increased pulsatile ﬂuid
shear stress (FSS) caused by the steep pressure gradient between the high
pre-occlusive and the very low post-occlusive pressure regions that are
interconnected by collateral vessels. Shear stress leads to the activation
and expression of all NOS isoforms and NO production, followed by
endothelial VEGF secretion, which induces MCP-1 synthesis in endothe-
lium and in the smooth muscle of the media. This leads to attraction and
activation of monocytes and T-cells into the adventitial space (peripheral
collateral vessels) or attachment of these cells to the endothelium
(coronary collaterals). Mononuclear cells produce proteases and growth
factors to digest the extra-cellular scaffold and allow motility and provide
space for the new cells. They also produce NO from iNOS, which is
essential for arteriogenesis. The bulk of new tissue production is carried
by the smooth muscles of the media, which transform their phenotype
from a contractile into a synthetic and proliferative one. Important roles
are played by actin binding proteins like ABRA, coﬁlin, and thymosin
beta 4 which determine actin polymerization and maturation. Integrins
and connexins are markedly up-regulated. A key role in this concerted
action which leads to a 2-to-20 fold increase in vascular diameter,
depending on species size (mouse versus human) are the transcription
factors AP-1, egr-1, carp, ets, by the Rho pathway and by the Mitogen
Activated Kinases ERK-1 and -2. In spite of the enormous increase in
tissue mass (up to 50-fold) the degree of functional restoration of blood
ﬂow capacity is incomplete and ends at 30% of maximal conductance
(coronary) and 40% in the vascular periphery. The process of
arteriogenesis can be drastically stimulated by increases in FSS
(arterio-venous ﬁstulas) and can be completely blocked by inhibition
of NO production, by pharmacological blockade of VEGF-A and by the
inhibition of the Rho-pathway. Pharmacological stimulation of arterio-
genesis, important for the treatment of arterial occlusive diseases, seems
feasible with NO donors.
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Modern research in arteriogenesis began with the
observations by Fulton [44, 46, 47] who developed a
new technique of postmortem injection into the
human coronary arteries consisting of high X-ray
contrast material combined with the use of ‘‘soft
X-rays’’ that produced images of such clarity and
precision that remained unchallenged even by mod-
ern imaging methods. From his research and that of
others it became clear that coronary artery occlusions
may not always lead to infarction. If infarcts had
occurred they may encompass only a fraction of the
region at risk and angina pectoris may occur less
frequently after some time due to the development of
collateral arteries from pre-existent interconnecting
arterioles. Baroldi [5] had provided ample and
deﬁnitive evidence on the basis of post mortem an-
giograms and corrosion-cast preparations that nor-
mal human coronary arteries are not end-arteries but
are interconnected with an arteriolar network that
considerably expands in cases of coronary occlusions.
This network is already present in the newborn. These
observations gave rise to hypotheses to be tested in
laboratory animals and after proﬁting from the gen-
eral progress in molecular and cellular biology the
mechanisms of arteriogenesis became much clearer
and new medicinal therapies are now being devel-
oped. Although the primary observations were almost
100 years old, battles are still fought today over
problems that had been phrased almost as long ago:
– are arteriolar collateral vessels pre-existent? can
collaterals form de-novo?
– what is the primary growth stimulus: chemical
(ischemia?) or physical?
– if physical, is it pressure or ﬂow related?
And new debates arose in recent years, namely:
– do angiogenic growth factors play a role and if yes
which one?
– are stem cells, adult or precursor, important for
arteriogenesis?
To position this review we will brieﬂy answer these
questions and furnish more detailed elaborations
further on.
Arteriogenesis: pre-existent and/or de-novo?
Fulton [46] and Baroldi [5] provided incontrovertible
evidence that coronary collateral arterioles exist in the
normal human heart that are potentially able to grow
into larger structures that are potentially able to save
myocardium from necrosis. Zbinden recently sup-
ported this view with functional data in beating nor-
mal human hearts studied with intra-coronary
measurements of wedge pressures and ﬂow wires
resulting in the collateral ﬂow index [166, 167]. Seiler
concluded that a well-trained normal human heart is
able to survive an acute coronary occlusion with only
minimal necrosis due to good collateralization [166].
This view, that pre-existent arteriolar connections
exist that enlarge by growth in response to arterial
occlusion, still stands today but is supplemented by
the opinion that capillaries may be able to recruit
smooth muscle and that muscular collateral arteries
can form de-novo [20]. Being a possibility, ﬁnal proof
that this process exists in mammalian hearts, that it
develops in the right place at the interface between a
normoxic and ischemic region and that it is
connected to an arterial pressure source and is able to
save or salvage muscular tissue is still lacking.
Collaterals do not form de-novo in the peripheral
circulation of rabbits, rats and mice. In man pre-
formed collateral pathways exist in the vascular
periphery that enlarge when stenoses form in the ili-
acal arteries with little inter-individual variation and
some are classiﬁed under speciﬁc names like ‘‘Rior-
dan’’ collaterals (see Ritter in ref. [125]). In rats a
particularly large collateral is visible with the un-
armed eye after contrast injection already before
occlusion which enlarges and carries most of the
collateral ﬂow [64]. A ﬁnite number of interconnect-
ing arterioles normally exists, 8 in C57BL/6J mice and
38 in rabbits, that enlarge after femoral occlusion
[129, 156]. The number of pre-existing collaterals
does not increase after arterial occlusion, not even
after maximal stimulation by increased shear stress.
The observed spurious increase in collateral number
in the rabbit hind leg is due to the limitations of
detection by X-ray based methods that recognize
vessels only after they pass the threshold of detection
by growth.
Is ischemia the stimulus for arteriogenesis?
Arterial occlusion leads to ischemia and to the
development of collateral vessels if conditions are
favorable and the occlusion develops gradually. It is
therefore suggestive to assume that ischemia is the
stimulus for arteriogenesis. However, stenoses slowly
progressing toward complete occlusions signify only
minimal ischemia, and this is the condition where
collaterals show their maximum of adaptation. Acute
infarctions are very poor stimuli for arteriogenesis:
scar tissue needs little perfusion. Often the ischemic
region and the location of growing collateral vessels
lie closely together, like in the heart, and make it
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starts and where exactly the growth occurs. However,
Fulton had already pointed out that the stem (origin)
of coronary collaterals in the human coronary circu-
lation expands already in normoxic tissue [44], a
consequence of the increased FSS. The problem is
easier to study in the peripheral circulation because of
the large distances between the point of arterial
occlusion and the location of ischemia. In the rabbit,
rat and mouse proximal femoral artery occlusion
leads to ischemia in the lower leg but not in the upper
leg where collaterals form [130] with the exception of
the white Balb/C mouse, a strain known for its paucity
of pre-existent collateral vessels [62]. A strong argu-
ment against a role of ischemia stems from recent
research in zebraﬁsh where the occlusion of the aorta
is rapidly compensated for by collateral vessel growth
in an environment that cannot become hypoxic [51].
An argument in favor of ischemia is the observation
that it is indeed the stimulus for the transcription and
translation of vascular endothelial growth factor
(VEGF), necessary for the angiogenic sprouting of
capillaries [93, 114, 133, 143]. We will explain later
that VEGF is indeed a necessary component of arte-
riogenesis but that ischemia is not the stimulus for
arteriogenesis because it is expressed in the endo-
thelium of growing collaterals that are constantly
perfused with well-oxygenated blood, and are by
deﬁnition not ischemic. The skeletal muscles sur-
rounding growing collaterals after femoral artery
occlusion in black mice are never ischemic (tested by
electron spin resonance resulting in normal muscular
pO2 and by magnetic resonance spectroscopy result-
ing in normal ATP and PCR values) [62, 156] but
collateral vessels develop nevertheless and much fas-
ter than in ischemic white mice under the same cir-
cumstances. Attraction of monocytes, essential for
arteriogenesis, is strongly inhibited by hypoxia [53].
Dogs, well endowed with native coronary collaterals,
react much faster with growth to repetitive occlusions
compared to dogs with a lesser-developed native
collateral network [42, 43]. Thus, the lesser the
ischemia, and the higher the FSS due to already
present collateral vessels, the faster the growth.
A prime example of shear stress-induced arterial
growth without accompanying ischemia is the out-
ward remodeling of the uterine artery during preg-
nancy [97]. We concludetherefore that ischemia, often
present at the time when collaterals develop, is not
necessary to explain the growth of collateral vessels.
It could still be argued that the venous return from
the ischemic lower limb in femoral artery occlusion
carries growth factors into the region where arterio-
genesis takes place. Although this is an untested
hypothesis we can argue that in our high shear stress
model where the collateral ﬂow was shunted directly
into the venous system the veins are perfused with
arterial blood andthe extremely high shunt ﬂow would
markedly dilute the inﬁnitely small amounts of hypo-
thetical factors. The initially and only brieﬂy ischemic
lower leg in black mice [62] recovers fast due to the
increaseincollateralﬂowbutalsoduetothedecreasein
metabolism [66] probably by hibernation and pre-
conditioning causing the rapid restoration of tissue
hemoglobin saturation at times of continuing active
collateralgrowth[125].Anecdotalevidenceexistsfrom
case reports where due to war wounds AV-shunts
persisted in the upper leg with the typical increased
vascularization in spite of lower leg amputation.
Pressure- or flow-derived stimuli?
It is generally assumed that a physical stimulus starts
the remodeling process whereby increased pressure
leads to increased wall thickness and increased ﬂow to
increased arterial diameter. Pressure-dependent forces
are by far the highest in magnitude and they affect
both the endothelium as well as the muscular media. It
is therefore logical to assume that these are important
factors for remodeling [83, 121, 122]. Vasodilatation of
the collateral arcade, which occurs after arterial
occlusion, may increase circumferential wall stress
according to Laplace’s Law because diameter increases
and wall thickness decreases, however, pressure falls
precipitously after occlusion and it is questionable
whether circumferential wall stress changes signiﬁ-
cantly. However, in collateral growth with its pressure
gradient driven increase in ﬂow the much weaker FSS,
which the viscous drag of ﬂowing blood exerts on the
endothelial lining, is the determining force [8, 17, 35,
49, 85, 114, 142, 145, 149]. However, pressure derived
pulsatile stretch is also discussed [83, 88, 110] and the
transcription factor AP-1 is the molecular transducer.
However, AP-1 is also activated by FSS [96]. Pulsatile
stretch can only be tested acutely and in vitro with its
inherent limits. Cultured endothelium under stretch
alters translation and transcription of growth factors
and changes the sensitivity to cytokines[14, 32, 110]. If
pulsatile stretch is a molding force it must be dem-
onstrated that in collateral growth pulsatile stretch is
higher than the physiological levels in normal small
arteries. Furthermore, in arterial occlusion the intra-
vascular pressure downstream from the occlusion
(and hence in the receiving end of the collateral
arcade) is much lower than the systemic arterial
pressure (100 mmHg proximal, 30 mmHg distal) and
the probability of increased stretch is low under
in-vivo conditions. In order to test the inﬂuence of
physicalforceswedesignedanexperimentwherepost-
occlusion pressure was lowered even more and where
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Collateral circulationﬂow was drastically increased by shunting the collat-
eral ﬂow directly into the venous system, which
maximized collateral growth [35, 106]. This experi-
ment clearly demonstrates that ﬂow dependent forces
had dominated growth.
The shear stress paradox
Although there is compelling evidence that FSS is the
primary morphogenic physical factor that determines
the size of an artery and in particular the size of a
growing collateral vessel, several problems still exist
[85, 113, 114]. FSS is a weak force that acts only on
endothelial cells in addition to the circumferential wall
stress (up to over one thousand times higher) that acts
both on endothelium and on the smooth muscles of
the media. It is at ﬁrst difﬁcult to understand that the
weak force directs the fate of the structures that cope
with and resist the strong force. However, numerous
physiological examples can be cited where weak forces
function as ampliﬁers. Another difﬁculty arises from
the fact that FSS falls precipitously with the 3rd power
of the radius when it increases due to growth.
One could argue that ﬂow increases, according to
Poissieulles Law, with the 4th power of the radius so
that with any increase in radius sufﬁcient shear stress
remains. However, these musings do not reﬂect reality
because ﬂow in the arterial circulation is never ideally
laminar and the exponent of the radius is probably
much less than 4 [58, 161]. By analogy the r-exponent
in the shear stress equation is therefore most certainly
less than 3 because the condition of laminarity is also
not met. Tortuosity, the typical feature of collateral
vessels, makes the issue of FSS even more complex
because shear stress in the outer curvature of a bend is
probably higher than the radius at that point would
predict. Curvature ﬂow, as described by the Dean
Equation [130] is part of the resistance in tortuous
collateral vessels but shear stress can be imagined to
be highest at the outer curvature.
Three observations suggest the leading role of the
endothelium in arteriogenesis: endothelial denudation
of the a. iliaca prevents positive remodeling after an
experimental AV-shunt [55], L-NAME and other
more speciﬁc inhibitors of eNOS prevent arteriogen-
esis and remodeling of collateral vessels, and after
arterial occlusion dedifferentiated smooth muscle
cells (SMCs) migrate toward the endothelium before
they divide and form the intimal layer of new cells.
If Circumferential Wall Stress (CWS) were the
morphogenic inﬂuence, proliferation should have
commenced at the outer, adventitial, SMC layer,
which according to the Law of Laplace, is markedly
more stretched.
However, if we assume FSS as the leading force of
arteriogenesis a new set of problems arise:
1. How are signals, generated in endothelial cells,
translated into a growth stimulus for the smooth
muscle layer of the media that is separated from
the endothelium by the internal elastic lamina? We
as well as others were unable to ﬁnd endothelial-to-
smooth muscle junctions in collaterals [122, 125],
which reduce the means of communication to
diffusible transmitters, like NO, oxygen radicals,
endothelin, and diffusible factors like VEGF.
Co-culture studies with endothelial- and SMCs in
close contact do not necessarily reﬂect the in-vivo
situation. This is highlighted by reports showing
that FSS decreases the expression of MCP-1 in
cultured endothelium, which is in contrast to the
in-vivo situation, and that FSS and NO reduce
monocyte attachment in vitro but the exact
opposite occurs during collateral artery growth
[125, 146, 147, 168].
2. Are special organelles like cilia, that protrude from
the endothelial surface and ﬂoat in the blood
stream and sense velocity, shear stress transducers
[67, 101, 108] or is the deformation of the entire
endothelial cell, the tensegrity model of Ingber,
required for gene activity typical for vascular
remodeling [72–75]? In our work in peripheral
arteriogenesis the presence of cilia could not be
veriﬁed on the basis of transmission and scanning
electron microscopy. Deformation of the endo-
thelium under high FSS is a typical feature of early
arteriogenesis and is ampliﬁed by the intracellular
edema and loss of volume control by activation of
ion channels [154]. This would stress the cyto-
skeleton similarly as in the tensegrity model.
3. Mathematical modeling of vessels arranged in par-
allel showed that FSS cannot be an organizing
principle of vessel growth because the model pre-
dicts instability with a preference for few but large
vessels [56]. However, this reﬂects arteriogenic
reality rather well. After arterial occlusion many
pre-existentarteriolesthatarearrangedmoreorless
in parallel start to grow but ﬁnally only a few large
ones emerge and the others are pruned away [129].
Increased FSS stimulated growth at ﬁrst but ended
when the competition had favored the large vessels
offering less resistance and normal FSS [125].
The study of collateral vessel development,
a personal history
The reason to study the role and development of
coronary collateral vessels in the mid1960s was the
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vasodilators that had been developed in the wake of
the success of Dipyridamole [79], developed with the
idea that vasoconstriction was the cause for angina
pectoris. Nitroglycerine, because it relieved the pain
of angina pectoris, was believed to relax spastic cor-
onary arteries but was too short acting and hence
longer acting vasodilators should improve the therapy
of angina. However, the newly developed coronary
angiography conﬁrmed earlier pathological ﬁndings,
in that coronary stenoses were structural and not
functional barriers and there was hence no place for
vasodilators. These, when applied in high doses,
caused angina instead of preventing it, a property
shared with high doses of nitroglycerine [162]. On the
other hand it was widely accepted that FSS, caused by
increased ﬂow velocity, i.e., by vasodilatation, is the
molding force for collateral vessels, at least in the
vascular periphery [139]. Chronic coronary vasodila-
tation should therefore support collateral enlarge-
ment. When we started to study the inﬂuence of a
long acting orally active coronary vasodilator, lido-
ﬂazine [127, 152], we noticed the paucity of functional
data about the collateral circulation. Although the
research by Fulton and Baroldi showed ample evi-
dence of their existence in the normal and patholog-
ical human heart, nothing much was known about the
mechanism of their structural enlargement. The pre-
vailing view was that they enlarged by stretch because
they appeared very thin walled [36, 45]. Also their
ability to functionally replace the occluded artery and
to what degree was unknown [52]. We could show, by
in-vivo pulse-labeling with tritiated thymidine and
uridine, that pre-existent coronary collaterals enlarge
by active proliferation of endothelial cells which pre-
ceded that of SMCs after DNA and RNA synthesis [25,
102, 123]. The degree of adaptation by growth was
impressive: in the canine heart (after gradual coronary
occlusion) the collateral diameter increased up to
20-fold and the tissue mass increased up to 50-fold.
To test for functional capacity was more difﬁcult:
only pressure-derived indices were initially available.
Peripheral coronary pressure measured in the distal
stump of the occluded artery was a good estimate
when divided by aortic pressure and when the mea-
surement was carried out under maximal vasodilata-
tion. The theoretical and experimental studies, that we
carried out in the mid 1970s for the validation of the
collateral ﬂow index (CFI) [104, 105, 126, 132], are
today used by clinicians in beating human hearts
[104, 166]. A much more precise method to measure
coronary and collateral ﬂow was the then (1970)
newly available tracer microsphere technique that we
perfected using semi-conductor crystal detectors and
a computer controlled automaton [163]. Our tracer
studies showed that in spite of the tremendous growth
of collateral vessels only one third of the maximal
conductance was replaced [124]. This is sufﬁcient for
the resting state and mild activities but not for heavy
physical exertion [65]. A wide margin for improve-
ment exists therefore for therapy. Our studies were
later conﬁrmed by Epstein’s group, who arrived at
exactly the same degree of adaptation [87].
Study of the histological structure and ultra
structure revealed that both endothelial as well as
SMCs went through a stage of dedifferentiation: SMCs
lost their contractile phenotype and assumed a syn-
thetic and proliferative phenotype, the latter also
prevailing in endothelial cells. The most striking
change was the migration of dedifferentiated SMCs
toward the endothelium, apparently an attractor. This
was enabled by the fragmentation of the internal
elastic lamina.
By employing scanning and transmission electron
microscopy in the study of collateral vessels at various
stages of maturation [117] we noticed in 1975 that
monocytes had attached to the formerly smooth but
now ‘‘rocky’’ endothelial surface at early stages of the
development [119] and had subsequently entered the
sub-endothelial space. The adventitial space became
invaded by bone marrow derived cells, mostly
T-lymphocytes, and it became clear that the process
of arteriogenesis exhibited an inﬂammatory scenario
[11]. Treatment with anti-inﬂammatory drugs
retarded the growth process showing that it was an
essential element [118].
In the early 1980s the ﬁrst angiogenic growth fac-
tors (GF) became known, notably PDGF [61] and FGF
[13], the latter isolated ﬁrst from brain tissue. Since
my interest was focused on coronary collaterals our
group tried to ﬁnd a factor produced by the myo-
cardium. Using a combination of chromatographic
methods we ﬁnally puriﬁed a very potent mitogen for
endothelial and SMCs from kilograms of bovine
hearts. The amino acid sequence revealed that it was
an already known factor, namely prostata growth
factor, which was shortly thereafter identiﬁed as
acidic Fibroblast Growth Factor, aFGF or FGF-1 [13,
112]. It was at ﬁrst difﬁcult to study the role of the
FGFs-1 and -2. Because of the perfect evolutionary
preservation of the genes it was not easy to produce
an antibody and even the construction of a probe for
in-situ hybridization had to take the detour via
the chicken sequence. When ﬁnally an antibody be-
came available we had FGF-1 adsorbed to porous
micro-beads and, when injecting them into the por-
cine coronary circulation, we could indeed show by
immuno-histochemistry the leaching of the factor
from the bead, its take-up into cells, its transport into
the nucleus and the subsequent mitosis [4]. However,
mitosis was only observed in interstitial ﬁbroblasts
but not in smooth or cardiac muscle cells. And the
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ﬁbroblasts after myocardial necrosis.
In growing collateral vessels after ameroid-induced
coronary occlusion we found FGF-1 in invading
monocytes [120]. This renewed our interest in mono-
cytes, especially since we found that porcine hearts
challenged with micro-embolism (Mohri in [120]) to
stimulate angiogenesis markedly up-regulated the
chemo-attractant JE, later called MCP-1, (monocyte
chemo-attractant protein1) [78, 157, 165].
The necessity to use smaller animals (new animal
protection legislation) forced us to abandon the study
of the coronary collateral circulation, ﬁrst, because
the ameroid technique of gradual coronary stenosis
was not applicable in mouse or rat hearts (a recent
report from Chilian’s group showed that this has
become feasible in the rat heart [144]), and second,
because pigs did not develop muscular collaterals
[25]. We concentrated therefore on the peripheral
circulation of the rabbit, rat and mouse, which
reduced the complexity of the experiments because
ischemic tissue loss played a relatively minor role
even after acute occlusions with the exception of the
white Balb C mouse with its poorly developed net-
work of peripheral collateral vessels [62, 130, 151].
The role of monocytes was tested by infusion into
the rabbit hindlimb of MCP-1 using osmotic mini-
pumps and it indeed stimulated arteriogenesis
markedly [77, 78]. The role of monocytes was further
strengthened by experiments showing that the
monocyte stimulant LPS, a Toll-like receptor ligand,
markedly stimulated arteriogenesis [3] and over-
expressed TNF-a [2, 68] but that reduction of blood
monocyte count with 5¢-ﬂuoro-uracil inhibited
arteriogenesis [2, 59]. Femoral ligature during the
monocyte rebound from cytotoxic treatment stimu-
lated it. Elimination of monocytes with nano-
encapsulated bisphosphonates strongly inhibited ar-
teriogenesis [107]. Over-transfusion with monocytes
stimulated arteriogenesis [59, 63] but animals genet-
ically lacking these cells (osteopetrotic mice and rats)
were almost unable to develop collateral vessels [9].
Genetically targeted mice lacking the gene for MCP-1
[153] and mice lacking the gene for the MCP-1
receptor (CCR2) exhibited a severely limited ability to
adapt to femoral artery occlusion [60]. These ﬁndings
and our observation that monocytes produce para-
crine growth factors may have been the basis for the
recent clinical and experimental interest in adult bone
marrow derived stem cells (which share markers with
monocytes and EPCs) for the regeneration of arterial
tissue. Murry in his Nature article supported this view
[100].
The increase in FSS as it occurs as a consequence
of increased collateral ﬂow due to the steep pressure
gradient across a stenosis or occlusion, tends to
prevent the attachment of monocytes and so we
studied the expression of adhesion molecules as a
counterforce and we found ICAM-1 and VCAM-1
greatly increased on the endothelial surface and in the
media of growing collaterals, more so in shunt stim-
ulated collaterals [106, 128]. Injection of antibodies
against ICAM and injection of the ICAM antigen re-
duced collateral development because the antigen
binds to the circulating monocytes and the antibody
blocks the docking site [69]. These experiments sup-
ported strongly again the important role of mono-
cytes in arteriogenesis.
Van Weel and co-workers as well as Epstein and his
group had recently shown that other leukocytes also
contributed to arteriogenesis, mainly T-lymphocytes,
NK-cells and CD4 and CD8 cells [137, 138, 151].
Endothelial progenitor cells were claimed to home to-
ward growing vessels and change their phenotype into
endothelial,smoothmuscleandeventocardiacmuscle
cells [80, 140]. Bone marrow derived cells from EGFP
chimaeras do indeed home toward growing collaterals
but never incorporateinto the vascular wall anddo not
change their phenotype but exhibit paracrine activity
instead [172].
Phases of remodeling
Roughly 4 stages in the development of a pre-existent
collateral arteriole into a mature small conductance
artery can be identiﬁed. Following a critical stenosis
or an acute occlusion a relatively silent phase of up to
2 days follows where nothing much happens in terms
of blood ﬂow increase. This is due to the fact that the
cell cycle and events leading to it require about one
day at which time point bone marrow derived cells
attach to the endothelium and gather in the adventi-
tial space. The hallmark of the ﬁrst phase is the
phenotypical change of endothelial and SMCs into
synthetic and proliferative ones with increase of vas-
cular permeability. The second phase is characterized
by the controlled destruction of the collateral vessel
by digestion of the extra-cellular scaffolding like
internal elastic lamina and extra-cellular matrix
simultaneously with a burst of mitotic activity of
SMCs and endothelial cells where the ECs precede
that of the SMCs by about one day. Phase 3 is the
maturation phase characterized by orderly arrange-
ment of the SMCs in circular layers, by establishment
of cell-to-cell contacts and by synthesis of elastin and
collagen to produce the new scaffold for the much
larger vessel. Phase 4 is characterized by pruning of
vessels that had initially participated in the remodel-
ing but are eliminated by the competition for ﬂow:
those with the initial advantage of a slightly larger
diameter reach maturation but many others close by
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closure of the stump of an occluded artery [129].
Structural restraints prevent full restitution of
function?
Theinabilityofexogenouslyappliedangiogenicgrowth
factors to fully restore the maximal conductance after
arterial occlusion led us to tackle the thus far unan-
swered question: are collaterals actually able to fully
replace the occluded artery? Can the limit of between
30%and40%restorationofphysiologicalconductance
bycollateralsbesurpassed?Whydoescollateralgrowth
stop prematurely? Is the tortuosity and increased
lengthofcollateralsananatomicallimit?Inordertotest
that problem we designed an experiment where the
pressure gradient along collaterals was further
increased and maintained for a relatively long time.
This was achieved by creating a side-to-side anasto-
mosis between the distal stump of the occluded artery
andtheaccompanyingvein,creatinganarterio-venous
shunt where the collateral blood ﬂow was largely
shunted directly into the venous system, which
increased markedly collateral ﬂow and FSS. This pro-
cedure greatly stimulated arteriogenesis and func-
tionally replaced the occluded artery already after one
week and increased the maximal conductance at
4 weeks after occlusion by a factor of two [35, 106].
With this experiment we showed that the 30%–40% of
spontaneous restoration of function was not caused by
anatomical restraints but rather by the premature
normalization of FSS, which falls with increases of the
vessel radius by the 3rd power. Our studies show that
therapeutic efforts are not doomed to fail because of
anatomical restraints and a reference point is deﬁned
that could and should be reached by therapy. The rea-
sons for premature stop of growth are twofold: shear
stress falls not onlybecausethevessel radiusincreases,
asdiscussedbutalsobecausemetabolicautoregulation
limits blood ﬂow to the actual need of the tissue.
Role of growth factors
Our ﬁndings that the FGF-1 protein is expressed in
the heart [112], that application of FGF-1 to heart
muscle stimulates mesenchymal cells to proliferate
[4], that monocytes loaded with FGF-1 home-in on
places where collateral vessels develop, that the
FGFR-1 is expressed in SMCs of growing collaterals
and in ﬁbroblasts of the adventitia [30] and that
transgenic myocardial over-expression increased ar-
teriogenesis and arterial branching in the heart [38]
were at ﬁrst interpreted that FGF-1 is the growth
factor of arteriogenesis [120]. Transgenic over-
expression of FGF-2 in skeletal muscle under the
control of the phosphoglycerate promoter resulted in
complete restoration of blood ﬂow after femoral ar-
tery occlusion, especially when combined with phys-
ical exercise [125]. Peripheral arteriogenesis following
femoral artery occlusion could be inhibited by PAS
(Polyanetholsulfonic acid), which blocks the action of
FGF by complex formation, which impairs binding to
the FGFR-1 [30]. FGF ligand availability did not
change, therefore regulation of arteriogenesis seemed
to proceed via receptor availability. In spite of all of
these ﬁndings the FGF-hypothesis has a low proba-
bility because gene-targeting of FGF-1, of FGF-2 and
the double knockout of FGF1 + 2 responded like
wild-type mice to femoral artery occlusion [170].
Except for changes in tibia length the animals were
normal and fertile. Since the FGF family is large the
assumption was that other members had substituted
in the gene-deleted animals. Adenoviral transfection
of rabbit skeletal muscle with FGF-4 stimulated arte-
riogenesis but no evidence is available that collateral
formation was stimulated in the FGF-1,-2 double
knockouts by FGF-4. Although FGF-7 is strongly ex-
pressed in cultured porcine vascular SMCs, especially
when stimulated with PDGF, no differential expres-
sion was found so far in developing collaterals. Mouse
knockout studies of FGF-7 showed no impaired
wound healing [54]. However, the triple knockout of
FGF 5, 6 and 7 markedly inhibited the recovery of
blood ﬂow after femoral artery occlusion (Zimmer-
mann et al. unpublished). In spite of the fact that
external application of FGF-1, -2, FGF-4, and -5
stimulate arteriogenesis [48, 87, 150], from about
40%–50% of physiological maximal conductance,
their internal role in collateral vessel development
remains uncertain.
An enormous amount of research was generated by
the discovery that vascular endothelial growth factor
(VEGF) played a crucial role in the embryonic genesis
of the vascular system. No offspring issued from
targeted deletion of the VEGF gene and not even
heterozygote knockouts were viable [21, 39].
Numerous studies were published showing that
application of VEGF either by protein or gene transfer
could reduce hind limb ischemia after femoral artery
occlusion in animals [7, 76, 164]. But in analogy with
the pioneering work of Epstein with FGF, complete
restoration of function of the occluded artery was not
reached. Our recent studies showed that VEGF-A
protein is indeed expressed on the endothelial surface
of growing collaterals which explains the mitotic
activity of the endothelium but not of the SMC pro-
liferation at a distance from the endothelium, espe-
cially because VEGF is not a mitogen for SMCs.
However, a combination of activated autologous EC
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VEGF retroviral vectors, respectively, produced
arteriogenesis in a hind limb ischemia model in
miniature pigs [50]. Recent studies by Terjung et al
showed that the arteriogenesis of exercise can be
inhibited by the VEGF antagonist ZD4190 [90].
Questions remain as to the mechanism of VEGF
expression by shear stress, which appears unorthodox
because VEGF is up regulated by hypoxia-inducible
factor (hif), but also by changes in glucose concen-
tration, in reaction to lowered oxygen tension [133],
which is high in arterial endothelium. A plausible
explanation for the interplay of factors might origi-
nate at shear stress activated eNOS which induces
VEGF which in turn induces MCP-1 in SMCs which
attracts monocytes which produce GFs and arterio-
genesis can be blocked at each mentioned point. The
action of growth factors, especially the FGFs and
VEGF, but also of the pleiotrophic heparin binding
growth factor Midkine are modulated by the synde-
cans (1–4), glycoproteins that act as co-receptors,
especialy for G-protein-coupled receptors [27, 28].
An ideal candidate for an endothelial FSS-activated
smooth muscle mitogen would be endothelin 1 [24].
Endothelin mRNA indeed reacts in our experiments
to FSS in a quantitative way, i.e. moderate increase
after simple femoral artery occlusion and marked
increase following shunt induced maximal shear
stress whereas in experiments of other groups it reacts
mainly to changes in pressure [86]. However, endo-
thelin is a strong antagonist of NO (and vice versa)
[12, 158] but NO is essential for arteriogenesis.
However, the observed increase of endothelin occurs
late during the maturation phase of the collateral
vessels where an antagonist of NO would be needed.
Another NOS inhibitor is hepatocyte growth factor
(HGF), which is produced by MCP-1 activated
monocytes [57]. However, HGF is not a known
mitogen for SMCs but it is angiogenic and a mitogen
and motogen for endothelial cells [16].
Uninhibited NO production could potentially fur-
ther stimulate collateral vessel growth. A similar effect
couldpotentiallybeinducedbyinhibitionofenzymatic
degradation of sGMP, the intracellular transmitter of
NO.Indeed,sildenaﬁl,ablockerofPDE-5,wasreported
to stimulate arteriogenesis [111, 134]. In our own
experiments in an ischemic rabbit hind limb prepara-
tion and with oral administration of high doses of sil-
denaﬁl the effect was marginal, probably caused by the
unknown pharmacokinetics in that species.
Cell–cell interactions
As discussed above, the arteriogenic process is initi-
ated by a sudden increase in shear stress. Shear stress
is sensed and transduced from the extra-cellular space
to the intracellular skeleton. Communication between
ECs and SMCs as a transverse signalling across the
vessel wall is required to initiate the proliferation
process. All these steps rely on cell-cell and cell-
matrix interactions.
Cellular effects of the extracellular matrix are pri-
marily mediated by integrins. Among the many
different isoforms aVb3 integrin is involved in angi-
ogenesis [41] as well as macrophage adhesion and
migration [159]. aVb3 integrin turned out to be
selectively increased in the wall of growing collateral
arteries during the ﬁrst 3 days after occlusion [37].
The speciﬁc localization of aVb3 integrin signals in the
abluminal surface of the endothelium is consistent
with observations, which were obtained in vitro [148].
However, increased expression under the inﬂuence of
high ﬂows shows integrin protein enwrapping all
vascular cells, which could explain the problem of
early signal transmission across the internal elastic
lamina before that is destroyed by the action of
elastase secreted by monocytes.
Nevertheless its main ligand vitronectin seemed
not to be involved in arteriogenesis [37]. In contrast
we found the integrin ligand ﬁbronectin up-regulated
in shunt-treated growing collaterals. Interactions
between ﬁbronectin and some syndecans can be
modulated by components of the extracellular matrix
proteins. Midkine, a heparin binding growth factor is
a ligand of a4b1- and a6b1-integrins [99].
Notch (receptor) in the SMCs and Jagged or Delta
(ligands) in the endothelium are membrane bound
proteins, mediating signals between cells in contact.
Fernandez and Broich already assumed a special rel-
evance of the Jagged/Notch signalling in embryonic
development of collateral arteries, as they have found
consistent, time-dependent, and cell-type restricted
regulation of Jagged and Notch protein expression
during the growth of collateral arteries [37]. Limbourg
et al. have shown that the ligand Dll1 regulates Notch
signalling-dependent Ephrin-B2 expression and het-
erozygous Dll1 mice show impaired arteriogenesis.
They could demonstrate that angiogenic GFs like
VEGF and FGF-2 regulate Ephrin B2 expression via
Dll1-dependent Notch activation [89]. Interaction
between endothelial arterial expressed EphB2 (that we
found up-regulated under high shear stress) and Eph
B4 receptor, which is expressed by venous endothelial
cells, regulates the integrity of the vessel wall, which
has to be preserved throughout the remodelling
process [84].
Electric currents or signalling molecules such as
Ca
2+ or IP3 between the ECs and SMCs could be
explained via gap junctions located at the smooth
muscle-endothelial interface called myoendothelial
junctions (MEJ). Although the functional evidence
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structural evidence for their existence in coronary as
well as in peripheral collateral vessels is lacking. At
least their frequencies are too low to explain the signal
transduction between endothelialcells (EC) and SMCs.
Connexins are proteins that form gap junctions.
Cx37, Cx40, Cx43 and Cx45 have been identiﬁed in
vascular cells, but the relative expression level differs
with vessel size/ location and species. Even the ﬂow
pattern seems to have effects on connexin expression
[33]. In the normal dog coronary system Cx37 and
Cx40 were only expressed in ECs while during col-
lateral growth SMCs, normally devoid of a junctional
system, strongly express Cx37 [19].
An interesting idea is the evidence indicating that
connexin proteins might also participate in cell-cell
communication via direct, transcellular protein-
protein interactions. The C-terminal portion of the
connexins is associated with a variety of cytoskeletal
proteins and, in conjunction with N-cadherin, is
linked to a number of cell signalling cascades [160].
The NO paradox
The enormous increase of collateral vessel density
and caliber and the drastic increase in function seen
in the shunt model raised the question about the
nature of the molecular pathways that had translated
FSS into a growth signal. We studied gene expression
in these rapidly growing vessels in the rat by genome-
wide screening of transcripts using micro-arrays.
Among the over 300 differentially expressed genes we
found several of the known stress-responsive genes
differentially expressed (klf2 [31, 40, 149], VEGFR/
PECAM complex [149], TRPV4 calcium channels
[141, 155]). We concentrated on the NOS isoforms
because we had previously found that the NOS
inhibitor L-NAME markedly inhibited the effects of
increased FSS [35, 125]. And indeed we found the
transcripts for eNOS, iNOS and nNOS signiﬁcantly
up-regulated both on the transcriptional as well as on
the translational level. These ﬁndings posed riddles
because NO is a powerful anti-mitogen [15, 70, 71].
The anti-proliferative actions of NO were even used
to successfully battle restenosis, based on intimal
SMC proliferation [1], after experimental angioplasty
[22, 103]. The antimitotic actions of NO are dose
dependent, at least in cells of the CNS that were
treated with the synthetic NO donor detaNONOate:
low doses of detaNONO are mitogenic but high doses
are antimitotic [95]. These effects could be modulated
by intracellular calcium concentrations. A similar
pro-mitogenic effect was obtained with sodium
nitroprusside in endothelial cells of the fetoplacental
artery via the MAPKinases ERK-1,-2 [169].
Given the strong inhibitory actions of NOS
antagonists it appeared logical to study mice with
genetically targeted deletions of the NOS isoforms.
However, surprisingly, we found that eNOS knock-
outs exhibited normal collateral vessel growth after
femoral artery occlusion and showed delayed recov-
ery only because of the prevailing intense vasocon-
striction, which was easily neutralized by NO-donors
[35, 71, 94, 125]. Only the additional inhibition of
iNOS in eNOS ko mice inhibited arteriogenesis to a
degree that led to auto-amputation (Schaper, sub-
mitted). L-NAME inhibits also iNOS, which explains
our results with L-NAME in the shunt experiments.
Irrespective of source, NO is an essential link in the
pathways leading to arteriogenesis. It may originate
also from the monocytes/macrophages in the peri-
vascular space where they are activated in an auto-
crine way and stimulated to produce mitogens. These
results also explain another spurious paradox, i.e., the
non-involvement of Akt [35], necessary for the
activation of eNOS [125] in our shunt studies.
It is of interest that for the experimental treatment
of cancer both eNOS and iNOS must be inhibited to
achieve an anti-angiogenic as well an anti-arteriogenic
effect [22].
An important discussion point is the question of
which comes ﬁrst in the reaction to FSS: NO or VEGF-A?
Both are known to be early responders and the arte-
riogenic actions of both can be stopped by inhibitors.
But what induces what? From a physiological point of
view NO must come ﬁrst because the immediate effect
of a step change in ﬂow occurs within seconds and is
NO-triggered vasodilatation [6, 109]. However, max-
imal phosphorylation at Ser 1177, a prerequisite for
eNOS to become active, requires 5 min and Ser 116
de-phosphorylation requires 30 min, too long to ex-
plain the acute hemodynamic effects of NO but per-
haps adequate for the transformation by growth [34].
It should also be noted that ischemic tissue is able to
produce NO by a non-enzymatic route [92]. All these
studies emphasize the essential role of NO and it
appears feasible that soon an NO releasing chemical
will be available for clinical testing to stimulate arte-
riogenesis. We have tested new direct and indirect NO
donors and found them to be impressively arterio-
genic.
The angiogenic and arteriogenic functions of NO
were inferred on the basis of inhibitor studies prior to
our results by Matsunaga [93] who also reported about
the interaction between VEGF and NO. Even before
that Guzman in 1997 reported the abrogation of
structural dilatation of arteries in arterio-venous
shunts by L-NAME. However, none of these authors
provided explanations or hypotheses about the
mechanisms of action of the anti-mitogen NO in a
process that totally relies on smooth muscle mitosis.
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Ziche already in 1994 [171] and recently the molecular
pathway was described on the basis of targeted dele-
tion of Rac-1 [116] a Rho-family member. With our
studies in shunt-stimulated collateral growth we also
described the involvement of the Rho-pathway in the
expression of ABRA, an actin-binding protein strongly
up-regulated in arteriogenesis. Arteriogenesis is also
inhibited by the Rho antagonist Fasudil [35].
SMC dynamics separates arteriogenesis from
angiogenesis
Most of the research in vascular remodeling had
concentrated on the endothelium, which indeed plays
a major role. However, the SMCs of the media are
responsible for most of the remodeling process of the
new artery. The marked changes from a contractile to
a synthetic and proliferative phenotype, the digestion
of the internal elastic lamina and the digestion of the
extra-cellular matrix, which allows motility are much
more profound compared to the mild morphological
changes that characterize the endothelium [117, 122,
129]. Motility is also inﬂuenced by massive changes in
the expression of integrins and the focal adhesion
kinases [98]. The stresses that arterioles undergo, that
normally do not exhibit contacts between endothelial-
and SMCs because of the interposed internal elastic
lamina, may have triggered the expression of conn-
exin Cx37 in SMCs, which was formerly only weakly
expressed in endothelium [18, 19]. The molecular
changes in smooth muscle dominate also the genomic
screens with the high expression of structural genes,
in particular smooth muscle actin, its degree of
polymerization and the numerous molecules that
bind actin at various stages (abra, coﬁlin [106], tsmb4
[136], destrin [106]). All these changes point toward a
potent mitogen for smooth muscle, the identity of
which is not yet known. An interesting hypothesis is
that the products of elastin cleavage, caused by
monocyte-derived proteases, are mitogenic and that
the loss of cell-to-cell contact itself triggers mitosis of
SMCs. Our studies with heterozygote deletion of the
elastin gene in mice showed accelerated arteriogenesis
(Szymanski et al. unpublished). Elastin digestion is
one of the prerequisites for positive remodeling.
We should keep in mind that situations exist where
SMCs proliferate in the absence of GFs [91].
Pathways and gene transcription
The translation of the shear stress signal into a
molecular pathway resulting in the activation of genes
coding for proteins that enable arteriogenic remod-
eling is only incompletely understood. In-vitro results
from stressed cultured endothelium are difﬁcult to
translate into an in-vivo situation where the shear
forces are so much higher. Furthermore, stressed
endothelium has to communicate with the underlying
smooth muscle layer from which it is normally sep-
arated by the internal elastic lamina. None of the
known endothelial stress-responsive proteins (klf2,
Tzima-complex [149], ion channels, etc) explain the
proliferation of the SMCs of the media but oxygen
based radicals generated in response to mechanical
stress may reach the SMCs and activate the tran-
scription factor AP-1 which in turn induces MCP-1
etc., [32]. Activation of transcription factors by radi-
cals would obviate the need for mitogens, which is in
some contrast to the ﬁndings by our group that
showed strong up-regulation of the MAPKinases
ERK-1/ERK-2, which transmit mitogenic messages
from cell membrane receptors to the nucleus [35, 125]
(see Fig. 1). Among the transcription factors involved
in arteriogenesis AP-1 [81] and the ‘‘early growth
response gene’’, egr-1 [29] play a prominent role
because they are activated by the MAPKinases ERK-
1,-2 and control the expression of GFs and adhesion
molecules as well as chemokines for mononuclear
cells [29]. Fittingly, egr-1 knockouts exhibited a
signiﬁcant delay in the blood ﬂow recovery after
femoral artery ligature [115]. We constructed an egr-1
reporter mouse by coupling of the egr-1 promoter to
luciferase and studied the animals in a ccd black box
in the hope to identify growing collaterals in a non-
invasive way. But mainly skeletal stress points (jaws
after feeding) lighted up after injection of Luminol
partially conﬁrming our hypothesis that mechanical
stresses are inducers of egr-1.
NOS antagonists drastically abrogate ERK activity,
which argues for an indirect inﬂuence of NO on a
mitogen-releasing cell. Another pathway that seems to
play a role is Rho signaling which appears to be
tightly coupled with the changes of actin polymeri-
zation that is typical for arteriogenesis. A co-tran-
scription factor that exhibits the highest up-regulation
(over 40-fold) in growing peripheral collateral vessels
in mouse, rat and rabbit is cardiac ankyrin repeat
protein carp (ANKRD1) [10]. The function of carp
[26, 173, 174] in the adult organism is unclear. During
embryonic development it regulates the expression of
GFs. Its up-regulation during adult arteriogenesis may
signify a recapitulation of embryonic mechanisms.
Carp was found to co-localize with a-actin in intimal
SMCs in human atherosclerotic lesions and could be
induced by activin, a member of the TGFb family in
experimental atherosclerosis [26]. Structural similar-
ities suggest that carp belongs to the early response
genes, which would partly explain its massive upreg-
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Targeted deletion of the three isoforms of ANKRD1
showed no delay in blood ﬂow recovery after femoral
artery occlusion [58].
A brief excursion into the clinical situation
The clinical ﬁeld of arteriogenesis is well covered by
excellent reviews [82, 131, 135]. Today clinicians use
techniques and insights gleaned from experimental
work and collateral hemodynamics can now be
studied in the beating hearts of fully conscious pa-
tients. The roles played by monocytes are fully rec-
ognized and are explored in studies making use either
of the paracrine action of monocytes in adult stem cell
applications, by chemokines that prolong the function
of monocytes like GM-CSF or G-CSF [132]o rb y
studying the gene expression of monocytes [23] with
the question in mind why only relatively few patients
are able to develop collaterals in spite of the fact that
all human hearts possess the precursors of grown
collateral arteries. Although these studies have
produced interesting results it must be kept in mind
that the development of collaterals needs time, which
is not granted in a situation of acute thrombotic
arterial occlusion. Those patients with a well-devel-
oped collateral circulation may have proﬁted from a
gradually developing stenosis via slow growth of
mural thrombi and not necessarily from a fortuitous
pattern of gene expression of monocytes.
In summary we have unraveled pathways essential
for arteriogenesis that converge to remodel a preex-
istent arteriole into an artery. These pathways origi-
nate at the shear stressed endothelium which attracts
bone marrow derived cells that produce GFs in
response to NO and VEGF and lead to powerful
remodeling mainly of the smooth muscle layer of the
media resulting in a manifold increase of the arteri-
olar diameter able to deliver bulk ﬂow to jeopardized
tissue. The multitude of morphological, protein-
biochemical and molecular changes seen in SMCs of
developing collaterals are of considerable interest but
they are only the consequences of the fundamental
event that occurred with mitogenic stimulation which
is still in need of unraveling.
Monocyte
FSS
MCP-1
TRPV
4 NOTC
H1
KLF
2
SRF
JUN
EGR1
RHOA
Abra
Dream
MAPK signaling
Proliferation
Cytoskeleton
reorganization
Dstn
TMSB4X
MAPK3 CFL1
DLL1 JAG1
NOS3 NOS1
NOS2
A
VEGF FN1
ITG
A5
NO
EFNB2
calcium
2+
Fig. 1 Network analysis of differentially expressed proteins (red symbols)
involved in arteriogenesis. We performed a literature scan (Pathway Studio) in
order to retrieve an extract of regulatory and interaction pathways. Different
ligands and receptors act in concert leading to an activation of a variety of
transcription factors and signalling pathways via the central players calcium
and NO. Bold arrows indicate a fluid shear stress activated new pathway, which
resulted from the molecular investigation of the shunt model. (FSS fluid shear
stress, MCP-1 monocyte chemo-attractant protein, Dll1 delta-like1, JAG1
jagged1, VEGF vascular endothelial growth factor, FN1 fibronectin, Trpv4
transient receptor potential cation channel, subfamily V, member 4, NOS1
neuronal nitric oxide synthase, NOS2A inducible nitric oxide synthase, NOS3
endothelial nitric oxide synthase, ITGA5: aVb3 Integrin, EFNB2 Ephrin B2, NO
nitric oxide, KLF2 Krueppel-like factor2, SRF serum response factor, EGR1 early
growth response1, RHOA ras homolog gene family, member A, CFL1 cofilin1,
Abra actin binding Rho activator, Dream DRE antagonist modulator, TMSB4X
thymosinb4, Dstn destrin)
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